Table 1.
Relationship between levels of Nuc-pYStat5 and other tumor variables in Cohort I
|
Nuc-pYStat5
n
(%) |
Fisher’s exact test, P | |||
|---|---|---|---|---|
| High | Low | |||
| GLUT1 |
High |
0 (0) |
9 (100) |
0.009 |
| Low |
20 (46.5) |
23 (53.5) |
||
| PrlR |
High |
9 (45) |
11 (55) |
0.561 |
| Low |
11 (34.4) |
21 (65.6) |
||
| Ki67 |
> = 15% |
11 (35.5) |
20 (64.5) |
0.770 |
| <15% |
9 (42.9) |
12 (57.1) |
||
| Histology |
IDC |
18 (39.1) |
28 (60.9) |
0.784 |
| ILC |
2 (50) |
4 (50) |
||
| ER/PR |
Positive |
18 (45.0) |
22 (55.0) |
0.100 |
| Negative |
2 (16.7) |
10 (83.3) |
||
| Total | 20 (38.5) | 39 (61.5) | 52 | |
*Positive (ER/PR) status means ER or PR is positive, whereas negative ER/PR status means that the specimen is negative for both receptors. Nuc-pYStat5, nuclear localized and tyrosine phosphorylated Stat5; GLUT1, glucose transporter 1; PrlR, prolactin receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor.